Imaging scientists achieved a major breakthrough when they proved it was possible to predict the onset of Alzheimer’s disease using PET scans of neurochemical activity. University of Michigan researchers are going for the next neuroimaging milestone by showing that the same technique can also aid in the differential diagnosis of dementia. More »
Mortality in elderly patients with dementia markedly and progressively increases with extended use of antipsychotics, according to the first long-term controlled study of risk in this population. Earlier evidence of this risk was from short-term trials not exceeding 14 weeks. More »
Alzheimer disease (AD) is more than twice as likely to develop in elderly persons with orthostatic hypotension (OH) as in those without OH, according to a new study presented at the Annual Meeting of the American Academy of Neurology. More »
Elderly persons with essential tremor (ET) are almost twice as likely to have dementia as those without ET, according to a new study from Elan Louis, MD, professor of neurology, and colleagues at Columbia University in New York. More »
The assessment and treatment of psychiatric symptoms in persons with cognitive dysfunction are becoming increasingly important. Prevalence estimates of dementia in the United States range from 5% in those aged 71 to 79 years to 25% to 50% in those 90 or older. More »
MRI measures of regional brain atrophy, taken at the University of California, San Diego, have established the basis for a new way to diagnose Alzheimer's disease. More »
Mortality in elderly patients with dementia markedly and progressively increases with extended use of antipsychotics, according to the first long-term controlled study of risk in this population. Earlier evidence of this risk was from short-term trials not exceeding 14 weeks. More »
MRI measures of regional brain atrophy, taken at the University of California, San Diego, have established the basis for a new way to diagnose Alzheimer's disease. More »
Fluorine-18 Pittsburgh Compound B, an imaging agent that could facilitate the early diagnosis of Alzheimer’s disease, has been used to identify amyloid deposition in the brains of cognitively normal adults. More »
A discovery about the brain protein KIBRA, commonly found in the kidneys and brain, could lead to future treatments for Alzheimer disease (AD). Investigators at the Translational Genomics Research Institute (TGen), lead by Corneveaux and Liang, in Phoenix found that the risk for AD is 25% lower in persons who carry the memory-enhancing KIBRA gene.1 This fi nding indicates that there might be a link between KIBRA and some of the proteins with which it interacts. More »
